These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 36841540)
1. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC. Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540 [TBL] [Abstract][Full Text] [Related]
2. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871 [TBL] [Abstract][Full Text] [Related]
3. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. Faivre-Finn C; Vicente D; Kurata T; Planchard D; Paz-Ares L; Vansteenkiste JF; Spigel DR; Garassino MC; Reck M; Senan S; Naidoo J; Rimner A; Wu YL; Gray JE; Özgüroğlu M; Lee KH; Cho BC; Kato T; de Wit M; Newton M; Wang L; Thiyagarajah P; Antonia SJ J Thorac Oncol; 2021 May; 16(5):860-867. PubMed ID: 33476803 [TBL] [Abstract][Full Text] [Related]
4. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Wadsworth C; Melillo G; Jiang H; Huang Y; Dennis PA; Özgüroğlu M; N Engl J Med; 2017 Nov; 377(20):1919-1929. PubMed ID: 28885881 [TBL] [Abstract][Full Text] [Related]
5. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). Socinski MA; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Gray JE; Park K; Vincent M; Mann H; Newton M; Dennis PA; Antonia SJ Clin Lung Cancer; 2021 Nov; 22(6):549-561. PubMed ID: 34294595 [TBL] [Abstract][Full Text] [Related]
6. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. Gray JE; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Kurata T; Chiappori A; Lee KH; Cho BC; Planchard D; Paz-Ares L; Faivre-Finn C; Vansteenkiste JF; Spigel DR; Wadsworth C; Taboada M; Dennis PA; Özgüroğlu M; Antonia SJ J Thorac Oncol; 2020 Feb; 15(2):288-293. PubMed ID: 31622733 [TBL] [Abstract][Full Text] [Related]
7. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. Garassino MC; Mazieres J; Reck M; Chouaid C; Bischoff H; Reinmuth N; Cove-Smith L; Mansy T; Cortinovis D; Migliorino MR; Delmonte A; Sánchez JG; Chara Velarde LE; Bernabe R; Paz-Ares L; Perez ID; Trunova N; Foroutanpour K; Faivre-Finn C J Thorac Oncol; 2022 Dec; 17(12):1415-1427. PubMed ID: 35961520 [TBL] [Abstract][Full Text] [Related]
8. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Kurata T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Faivre-Finn C; Reck M; Vansteenkiste J; Spigel DR; Wadsworth C; Melillo G; Taboada M; Dennis PA; Özgüroğlu M; N Engl J Med; 2018 Dec; 379(24):2342-2350. PubMed ID: 30280658 [TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496 [TBL] [Abstract][Full Text] [Related]
10. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab. Nindra U; Shahnam A; Stevens S; Pal A; Nagrial A; Lee J; Yip PY; Adam T; Boyer M; Kao S; Bray V Asia Pac J Clin Oncol; 2024 Feb; 20(1):16-24. PubMed ID: 36855021 [TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R. Filippi AR; Bar J; Chouaid C; Christoph DC; Field JK; Fietkau R; Garassino MC; Garrido P; Haakensen VD; Kao S; Markman B; McDonald F; Mornex F; Moskovitz M; Peters S; Sibille A; Siva S; van den Heuvel M; Vercauter P; Anand S; Chander P; Licour M; de Lima AR; Qiao Y; Girard N ESMO Open; 2024 Jun; 9(6):103464. PubMed ID: 38833971 [TBL] [Abstract][Full Text] [Related]
12. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Faivre-Finn C; Spigel DR; Senan S; Langer C; Perez BA; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Hui R; Murakami S; Paz-Ares L; Broadhurst H; Wadsworth C; Dennis PA; Antonia SJ Lung Cancer; 2021 Jan; 151():30-38. PubMed ID: 33285469 [TBL] [Abstract][Full Text] [Related]
13. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Spigel DR; Faivre-Finn C; Gray JE; Vicente D; Planchard D; Paz-Ares L; Vansteenkiste JF; Garassino MC; Hui R; Quantin X; Rimner A; Wu YL; Özgüroğlu M; Lee KH; Kato T; de Wit M; Kurata T; Reck M; Cho BC; Senan S; Naidoo J; Mann H; Newton M; Thiyagarajah P; Antonia SJ J Clin Oncol; 2022 Apr; 40(12):1301-1311. PubMed ID: 35108059 [TBL] [Abstract][Full Text] [Related]
14. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer. Mooradian MJ; Cai L; Wang A; Qiao Y; Chander P; Whitaker RM JAMA Netw Open; 2024 Apr; 7(4):e247542. PubMed ID: 38648057 [TBL] [Abstract][Full Text] [Related]
15. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial). Choi J; Lee JE; Choi CM; Oh IJ; Lee KY; Jang TW; Lee SH; Kim EY; Park DW; Park SH; Lee SY Thorac Cancer; 2022 Dec; 13(23):3431-3435. PubMed ID: 36259253 [TBL] [Abstract][Full Text] [Related]
16. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives. Kato T; Casarini I; Cobo M; Faivre-Finn C; Hegi-Johnson F; Lu S; Özgüroğlu M; Ramalingam SS Lung Cancer; 2024 Jan; 187():107414. PubMed ID: 38088015 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations. Cortiula F; De Ruysscher D; Steens M; Wijsman R; van der Wekken A; Alberti M; Hendriks LEL Eur J Cancer; 2023 May; 184():172-178. PubMed ID: 36931075 [TBL] [Abstract][Full Text] [Related]
18. MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC. Reck M; Nadal E; Girard N; Filippi AR; Martin LW; Gay CM; Petersen C; Gale D; Emeribe UA; Georgoulia N; Perez IED; Spicer JD Clin Lung Cancer; 2024 Sep; 25(6):587-593.e3. PubMed ID: 39003185 [TBL] [Abstract][Full Text] [Related]
19. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Paz-Ares L; Spira A; Raben D; Planchard D; Cho BC; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Hui R; Murakami S; Spigel D; Senan S; Langer CJ; Perez BA; Boothman AM; Broadhurst H; Wadsworth C; Dennis PA; Antonia SJ; Faivre-Finn C Ann Oncol; 2020 Jun; 31(6):798-806. PubMed ID: 32209338 [TBL] [Abstract][Full Text] [Related]
20. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer. Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]